Article type
Abstract
"Background: Febrile neutropenia, anemia and thrombocytopenia often occur following patients with myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays.
Objective: The purpose of this study was to establish an evidence-based myelosuppressive care model for cancer patients receiving chemotherapy and to explore the effects of the myelosuppressive care model for cancer patients to decrease the incidence of infection, sepsis, anemia, or bleeding and severity of symptoms.
Methods: A 12-week two-group quasi-experimental design was used and to investigate the effectiveness of this myelosuppressive care model to cancer patients receiving chemotherapy. Totally 6 digestive oncology wards including 174 cancer patients were assessed from a medical center. The myelosuppressive care model named as NATIDE bundles was provided as Neutropenia care, Anemia care, Thrombocytopenia care, Infection control, Dietary requirements and Education. Research instruments as the myelosuppressive care checklist, patient self-report log, patients’ reported severity of symptoms, and 36-item short form health survey were used. The generalized estimation equation (GEE) of health-related outcomes from two groups was computed and analyzed.
Results: The findings were the following:(1) Of 174 patients, there were 99 patients in the control group and 75 patients in the experimental group; (2) The incidence of febrile, neutropenia, anemia and thrombocytopenia was 0.0%, 3.7%, 12.8%, 0.0%, respectively; (3) There was a significant difference in the patients’ reported severity of symptoms between the 2 groups in the 12-week study period; (4) There was no significant difference in the SF-36 health-related outcomes between the 2 groups in the 12-week study period.
Conclusions: The result of this study is to develop an evidence-based myelosuppressive care model for general hospitalized cancer patients receiving chemotherapy and to provide the implementation of this NATIDE bundles care. It could prevent or decrease the incidence and duration of infection, sepsis, anemia, or bleeding, severity of symptoms, length of stay, and medical cost. Furthermore, it would be recommended expanding this myelosuppressive care guideline to other cancer care settings.
Keywords: Myelosuppressive care, evidence-based practice model, cancer patients receiving chemotherapy"
Objective: The purpose of this study was to establish an evidence-based myelosuppressive care model for cancer patients receiving chemotherapy and to explore the effects of the myelosuppressive care model for cancer patients to decrease the incidence of infection, sepsis, anemia, or bleeding and severity of symptoms.
Methods: A 12-week two-group quasi-experimental design was used and to investigate the effectiveness of this myelosuppressive care model to cancer patients receiving chemotherapy. Totally 6 digestive oncology wards including 174 cancer patients were assessed from a medical center. The myelosuppressive care model named as NATIDE bundles was provided as Neutropenia care, Anemia care, Thrombocytopenia care, Infection control, Dietary requirements and Education. Research instruments as the myelosuppressive care checklist, patient self-report log, patients’ reported severity of symptoms, and 36-item short form health survey were used. The generalized estimation equation (GEE) of health-related outcomes from two groups was computed and analyzed.
Results: The findings were the following:(1) Of 174 patients, there were 99 patients in the control group and 75 patients in the experimental group; (2) The incidence of febrile, neutropenia, anemia and thrombocytopenia was 0.0%, 3.7%, 12.8%, 0.0%, respectively; (3) There was a significant difference in the patients’ reported severity of symptoms between the 2 groups in the 12-week study period; (4) There was no significant difference in the SF-36 health-related outcomes between the 2 groups in the 12-week study period.
Conclusions: The result of this study is to develop an evidence-based myelosuppressive care model for general hospitalized cancer patients receiving chemotherapy and to provide the implementation of this NATIDE bundles care. It could prevent or decrease the incidence and duration of infection, sepsis, anemia, or bleeding, severity of symptoms, length of stay, and medical cost. Furthermore, it would be recommended expanding this myelosuppressive care guideline to other cancer care settings.
Keywords: Myelosuppressive care, evidence-based practice model, cancer patients receiving chemotherapy"